Ipsen has acquired Epizyme, a biopharmaceutical company.
The acquisition focuses on the drug Tazverik, an EZH2a inhibitor that does not require chemotherapy.
“Through this agreement, we will expand our assets in oncology. Ipsen’s capabilities and resources in oncology combined with Epizyme’s will accelerate the growth of Tazverik to achieve its full potential in follicular lymphoma patients. Furthermore, we are excited to bring on board epigenetic expertise, as well as several pre-clinical compounds into our portfolio,” said David Loew, CEO of Ipsen.
Barclays is acting as financial advisor to Ipsen, and Orrick Herrington & Sutcliffe LLP as legal counsel to Ipsen. Jefferies and MTS Health Partners are acting as financial advisors to Epizyme, with WilmerHale serving as legal counsel.